rasburicase (Elitek)

06/01/2017 - "Rasburicase was highly effective in the prevention and management of hyperuricemia, even at a low-dose (7.5 mg/day) and a duration that was 3 days shorter compared with that recommended by the manufacturer. "
06/01/2012 - "Rasburicase is highly effective for prevention and management of hyperuricemia in adults at risk for TLS. "
01/01/2008 - "A single dose of rasburicase is highly effective and well tolerated in the treatment of hyperuricemia in selected CKD patients."
01/01/2006 - "Although further pharmacoeconomic data would be useful, rasburicase was most cost effective for the prevention of hyperuricemia in children and for treatment of this condition in adults. "
09/01/2010 - "Shorter courses or smaller doses of rasburicase than those recommended may be effective in reducing hyperuricemia in some patients, but it is important to recognize that the alternative dosing still awaits validation. "

02/01/2009 - "Rasburicase is very effective in the prevention of acute tumour lysis syndrome. "
01/01/2018 - "Single dose Rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden."
07/01/2021 - "There are several opportunities for improvement in tumor lysis syndrome management and rasburicase utilization at our institution. "
07/01/2021 - "Of the patients who had tumor lysis syndrome laboratory values collected post rasburicase, 39% were appropriately timed to accurately assess efficacy of rasburicase with the median time of laboratory monitoring after rasburicase being 6.5 h. "
10/01/2018 - "Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome."

08/01/2013 - "It suggests that the single-dose rasburicase is clinically effective and cost efficient for the prophylaxis of high-risk TLS and the treatment of hyperuricaemia in adult patients with cancer. "
02/15/2022 - "Rasburicase is associated with better outcomes regarding remission of the underlying malignancy. "
04/01/2002 - "Rasburicase is a safe and effective agent in the prevention or treatment of hyperuricaemia in cancer patients."
02/15/2022 - "Rasburicase use (HR = 2.45, IC 95% [1.17-5.15]) was associated with remission of the underlying malignancy at 1 year. "
04/01/2002 - "To date, rasburicase has been tested in four clinical trials conducted in patients with cancer (primarily haematological malignancies). "

03/01/2015 - "With data and studies proving a similar efficacy for the reduced dose and lesser number of rasburicase, we report here a case series of seven children with acute leukemias, whose TLS was managed by a single dose of rasburicase. "
01/01/2022 - "Management of Hyperleukocytosis in Childhood Acute Leukemia Without Leukapheresis and Rasburicase Prophylaxis."
01/01/2021 - "Eligible pts aged ≥ 18 years old with acute leukemia and UA ≥ 7.5 mg/dL were randomized to receive an initial single dose of rasburicase 1.5 mg (Arm A) or 3 mg (Arm B) on day 1 in an unblinded fashion. "
01/01/2021 - "To prospectively determine the efficacy and safety of two single low doses of rasburicase in adult patients (pts) with acute leukemia and elevated plasma UA. "
06/01/2023 - "Despite rasburicase's proven efficiency in Caucasians, Japanese, and Koreans, studies evaluating the safety and effectiveness of rasburicase in Chinese pediatric patients with non-Hodgkin's lymphoma (NHL) and acute leukemia (AL) in particular are lacking. "

10/01/2018 - "The study included 186 patients with hematological malignancies who received rasburicase. "
11/01/2009 - "This study in Japanese patients evaluated the efficacy, safety, and pharmacokinetic profile of rasburicase in pediatric patients with hematologic malignancies. "
05/01/2015 - "To define the efficacy and safety of low-dose rasburicase in children from south India with hematologic malignancies. "
05/01/2015 - "Low-dose rasburicase in hematologic malignancies."
11/01/2009 - "Patients aged <18 years at high risk for TLS, with newly diagnosed hematologic malignancies, were randomized to intravenous rasburicase 0.15 mg/kg/day (n = 15) or 0.20 mg/kg/day (n = 15) for 5 days. "